What is Refludan used for?
Refludan is indicated for patients who have
had a reaction to heparin that resulted in reduced
platelets and associated blood clots, in order to
prevent more clotting complications
Who should not be treated with Refludan?
You should not be given Refludan if you are
allergic to this drug or similar drugs.
Special Warnings for Refludan:
Bleeding is the most common complication of
Refludan. If you have the following conditions, your
risk of bleeding may be increased:
- Recent puncture of large vessels or organ
biopsy
- Abnormality of blood vessels or organs
- Recent "mini-stroke," stroke,
brain surgery, or other central nervous system
procedure
- Uncontrolled severe high blood pressure
- Infection of the heart lining (endocarditis)
- Advanced kidney damage
- Tendency to bleed
- Recent major surgery
- Recent major bleeding
General Precautions with Refludan:
- Your doctor will monitor your treatment
by using a test that measures the clotting time
of your blood.
- The dosage of Refludan may be decreased
if you have liver or kidney disease.
What should I tell my doctor or health care provider?
Because certain other medications can interact
with Refludan, and increase the risk of bleeding,
review all medications that you are taking with your
health care provider, including those that you take
without a prescription. Other drugs that break up
or dissolve clots, such as (rt-PA) or streptokinase,
or drugs that prevent clots such as Coumadin, warfarin,
or aspirin, can increase your risk of bleeding.
What are some possible side effects of Refludan?
(This
is NOT a complete list of side effects
reported with Refludan. Your health care provider
can discuss with you a more complete list of side
effects.)
Bleeding was the most common adverse event
reported during testing of the product. Bleeding
can be severe.
Other side effects occurring in at least 2%
of the people studied:
- Abnormal liver function
- Allergic skin reactions
For more detailed information about Refludan, ask
your health care provider.
Revised: 7/25/00 |
Notice: The